MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Interpace Biosciences Net Debt 2011-2026 | IDXG
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Interpace Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 K | -1.65 M | -2.4 M | -1.39 M | 1.97 M | 4.78 M | -6.07 M | -15.2 M | 7.31 M | 87 K | 4.15 M | -45.6 M | -52.8 M | -64.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.31 M | -64.3 M | -12.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.03 | -2.26 % | $ 98.3 K |  USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
-6.88 M | $ 23.35 | -2.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 34.5 | 2.16 % | $ 371 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.29 | -12.26 % | $ 1.64 M | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 39.74 | 1.48 % | $ 1.1 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
13.6 B | $ 219.29 | -0.08 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-560 M | $ 102.41 | 0.1 % | $ 19 B | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 26.19 | -0.19 % | $ 792 M | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
646 M | $ 113.17 | 2.43 % | $ 13.9 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
-487 M | $ 73.31 | -0.93 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
-48 M | $ 20.55 | -1.23 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
82.8 M | $ 109.48 | -2.35 % | $ 4.32 B | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.2 | -0.97 % | $ 289 M | Israel |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
-346 M | $ 66.91 | 0.34 % | $ 4.63 B | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 144.81 | -3.26 % | $ 23 B | USA |
 |
NeoGenomics
NEO
|
-23.3 M | $ 11.99 | -3.35 % | $ 1.52 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
11.2 B | $ 230.33 | -2.19 % | $ 41.8 B | USA |
 |
Charles River Laboratories International
CRL
|
2.1 B | $ 210.51 | -0.59 % | $ 10.8 B | USA |
 |
Personalis
PSNL
|
-48.8 M | $ 9.33 | -6.42 % | $ 553 M | USA |
 |
Medpace Holdings
MEDP
|
-520 M | $ 582.66 | -1.76 % | $ 18 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 186.45 | 2.27 % | $ 20.7 B | USA |
|
Biodesix
BDSX
|
14.5 M | $ 10.11 | 4.66 % | $ 1.31 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-1.18 M | $ 24.07 | -0.78 % | $ 31.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4 B | $ 271.34 | 0.56 % | $ 22.8 B | USA |
 |
Mettler-Toledo International
MTD
|
1.8 B | $ 1 370.47 | -1.61 % | $ 29.1 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 181.44 | -2.39 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
183 M | $ 672.84 | -0.57 % | $ 55.5 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 28.66 | -2.02 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
1.24 B | $ 133.33 | 0.07 % | $ 40.5 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.41 | 0.84 % | $ 5.54 M | USA |